Artal Group S.A. Has $1.90 Million Stake in MacroGenics Inc (MGNX)

Artal Group S.A. decreased its position in shares of MacroGenics Inc (NASDAQ:MGNX) by 50.0% during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 100,000 shares of the biopharmaceutical company’s stock after selling 100,000 shares during the quarter. Artal Group S.A.’s holdings in MacroGenics were worth $1,900,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. Parametric Portfolio Associates LLC acquired a new stake in shares of MacroGenics during the 2nd quarter worth approximately $203,000. Teacher Retirement System of Texas acquired a new stake in shares of MacroGenics during the 4th quarter worth approximately $225,000. Virtu KCG Holdings LLC acquired a new stake in shares of MacroGenics during the 2nd quarter worth approximately $232,000. Private Capital Advisors Inc. acquired a new stake in shares of MacroGenics during the 4th quarter worth approximately $332,000. Finally, Cornerstone Capital Management Holdings LLC. grew its stake in shares of MacroGenics by 3.8% during the 2nd quarter. Cornerstone Capital Management Holdings LLC. now owns 23,238 shares of the biopharmaceutical company’s stock worth $406,000 after purchasing an additional 848 shares during the period. 83.18% of the stock is currently owned by institutional investors and hedge funds.

MacroGenics Inc (MGNX) opened at $23.30 on Friday. MacroGenics Inc has a 52-week low of $14.36 and a 52-week high of $24.26. The stock has a market capitalization of $849.22, a P/E ratio of -5.19 and a beta of 2.79.

MGNX has been the topic of a number of analyst reports. Cowen reaffirmed a “buy” rating on shares of MacroGenics in a research note on Wednesday, October 25th. Citigroup raised their price objective on shares of MacroGenics from $18.00 to $22.00 and gave the stock a “neutral” rating in a research note on Friday, November 10th. ValuEngine lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Tuesday, November 14th. Raymond James Financial reiterated a “buy” rating on shares of MacroGenics in a research report on Monday, December 11th. Finally, BidaskClub lowered MacroGenics from a “sell” rating to a “strong sell” rating in a research report on Thursday, December 14th. One equities research analyst has rated the stock with a sell rating, four have given a hold rating and nine have issued a buy rating to the company’s stock. MacroGenics presently has a consensus rating of “Buy” and an average price target of $30.60.

In other MacroGenics news, SVP Jon Marc Wigginton sold 5,000 shares of the firm’s stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $20.00, for a total value of $100,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, SVP Eric Blasius Risser sold 3,000 shares of the firm’s stock in a transaction on Wednesday, January 24th. The shares were sold at an average price of $22.50, for a total value of $67,500.00. Following the completion of the transaction, the senior vice president now owns 12,100 shares in the company, valued at approximately $272,250. The disclosure for this sale can be found here. Insiders have sold a total of 13,000 shares of company stock worth $267,500 in the last quarter. Insiders own 8.30% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece was posted by Week Herald and is the sole property of of Week Herald. If you are viewing this piece on another domain, it was stolen and reposted in violation of international trademark & copyright laws. The correct version of this piece can be viewed at https://weekherald.com/2018/02/18/artal-group-s-a-has-1-90-million-stake-in-macrogenics-inc-mgnx.html.

MacroGenics Profile

MacroGenics, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing monoclonal antibody-based therapeutics for the treatment of cancer, as well as various autoimmune disorders and infectious diseases. The Company develops therapeutic product candidates using its antibody-based technology platforms and also in collaboration with other biopharmaceutical companies.

Want to see what other hedge funds are holding MGNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for MacroGenics Inc (NASDAQ:MGNX).

Institutional Ownership by Quarter for MacroGenics (NASDAQ:MGNX)

Receive News & Ratings for MacroGenics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MacroGenics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply